• Anti-VEGF for Macular Edema: Monthly or Treat-and-Extend?

    Written By: Lynda Seminara
    Selected By: Neil M. Bressler, MD, and Deputy Editors

    In a randomized clinical trial, the Study of Comparative Treatments for Retinal Vein Occlusion 2 established that, in the first 6 months of treatment, bevacizumab, on average, does not result in inferior visual acuity outcomes when compared to aflibercept for managing macular edema from central retinal or hemiretinal vein occlusion.